Gene therapy (AAV vector) · Gene replacement: spinal muscular atrophy with bi-allelic SMN1 mutations · developed by Novartis Innovative Technologies
Onasemnogene abeparvovec is an AAV9-based gene therapy that delivers a copy of the human SMN1 gene encoding the survival of motor neuron (SMN) protein, which is insufficiently expressed in spinal muscular atrophy caused by bi-allelic SMN1 mutations.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 16, 2026). Read the full label for the exact wording, limitations and safety information.
Spinal Muscular Atrophy
Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →